EGFR and non-small cell lung carcinoma: In this study, we report the findings on the cardiac safety of lazertinib at doses ranging from 20 to 320 mg/d in patients with EGFRm locally advanced or metastatic NSCLC who had previously received EGFR TKI treatment.